EPR26-152: GLP-1 and Dual Agonists and the Incidence of Skin Cancer: Evidence from Randomized Controlled Trials.
Analysis of major trials addresses safety concerns about GLP-1 drugs and potential cancer risk, informing prescribing decisions.
This JNCCN abstract analyzes skin cancer incidence from randomized controlled trials of GLP-1 and dual agonists. It addresses emerging safety concerns about GLP-1 class drugs and malignancy risk.
What the study was
- Study design
- Meta-analysis of RCTs
- Population
- Patients on GLP-1/dual agonists
- Category
- Prevention
- Maturity
- Validated
- Journal
- Journal of the National Comprehensive Cancer Network
Why it surfaced
Timely safety signal analysis for GLP-1 drugs and cancer risk from RCT data. Conference abstract format.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.